Taking Stock Of Stocks

Aiming to be Asia's No. 1 skin-health firm

In this monthly series, The Sunday Times and Singapore Exchange's research team interview company bosses to help investors get a better look at a firm's operations, one that goes beyond the financials. We speak to Hyphens Pharma chief operating officer Yann Marche.

A Our principal business, the most important one, is the speciality pharmaceuticals segment. Today, our strategy is to preserve and consolidate our existing partnership with our principal brands.

For example, Guerbet is a French pharma company specialising in contrast agents used in medical imaging. We have been partnering this firm for more than 25 years.

Please or to continue reading the full article.

Get unlimited access to all stories at $0.99/month

  • Latest headlines and exclusive stories
  • In-depth analyses and award-winning multimedia content
  • Get access to all with our no-contract promotional package at only $0.99/month for the first 3 months*

*Terms and conditions apply.

A version of this article appeared in the print edition of The Sunday Times on December 08, 2019, with the headline 'Aiming to be Asia's No. 1 skin-health firm'. Print Edition | Subscribe